Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$355.1B
2,467M shares
52-week range
$77.58 – $156.92
84% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
P/S (TTM)
5.4
EV / FCF (TTM)
25.1
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
www.merck.comNo one on the platform currently holds MRK.
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2025-12-31 | 310,221 | $32.7M |
| Renaissance Technologiesas of 2025-06-30 | 139,820 | $11.1M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-09-15 | $0.8500 | 2026-10-07 |
| 2026-06-15 | $0.8500 | 2026-07-08 |
| 2026-03-16 | $0.8500 | 2026-04-07 |
| 2025-12-15 | $0.8500 | 2026-01-08 |
| 2025-09-15 | $0.8100 | 2025-10-07 |
| 2025-06-16 | $0.8100 | 2025-07-08 |
| 2025-03-17 | $0.8100 | 2025-04-07 |
| 2024-12-16 | $0.8100 | 2025-01-08 |
| 2024-09-16 | $0.7700 | 2024-10-07 |
| 2024-06-17 | $0.7700 | 2024-07-08 |
No one on the platform has traded MRK yet.
| 2024-03-14 | $0.7700 | 2024-04-05 |
| 2023-12-14 | $0.7700 | 2024-01-08 |
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 23.0% | 18.2% | 14.3% | — | — | — |
| Rev. Growth % | 1.2% | 9.4% | ||||
| Profit Margin % | 28.1% | 21.3% | 17.9% | |||
| Free Cash Flow Margin % | 19.0% | 21.4% | 20.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +24.6% on the P/E track.
At today's price, your expected annual return is +30.9% on the P/E track.
At today's price, your expected annual return is +36.5% on the P/E track.
Also held through funds
2 more books hold MRK indirectly · AVUS 0.6% of fund, VTI 0.5% of fund
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $67.1B | +3.5% | $2.75 | $2.52–$4.20 | 52.4× | 14 |
| 2027 | $70.2B | +4.6% | $9.55 | $9.10–$9.94 | 15.1× | 14 |
| 2028 | $74.4B | +6.0% | $10.55 | $8.55–$12.60 | 13.6× | 8 |
| 2029 | $74.7B | +0.4% | $10.32 | $10.05–$10.67 | 13.9× | 5 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $-0.27 | $-0.13 | +51.9% |
| 2026-04-30 | $-1.47 | $-1.28 | +12.9% |
| 2026-02-03 | $2.01 | $2.04 | +1.5% |
| 2025-10-30 | $2.36 | $2.58 | +9.3% |
| 2025-07-29 | $2.03 | $2.13 | +4.9% |
| 2025-04-24 | $2.13 | $2.22 | +4.2% |
| 2025-02-04 | $1.85 | $1.72 | -7.0% |
| 2024-10-31 | $1.50 |
| $1.57 |
| +4.7% |
| $180.5B |
| — |
| GSKGSK plc | $50.18 | +4.27% | $100.5B | — |
| NVONovo Nordisk A/S | $43.47 | +0.94% | $193.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$CATX has announced a clinical trial collaboration agreement with $MRK to evaluate its targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in patients with certain types of non-small cell lung cancer and colorectal cancer that express fibroblast activation protein alpha (FAP-α). https://biotuesdays.com/2026/09/14/perspective-and-merck-collaborate-on-study-of-combined-therapies-in-fap-α-solid-tumors/
View on StockTwits ↗
$CATX Merck’s new PSV359–Keytruda collaboration validates another CATX program, making CATX look more like a multi-asset Pb-212 platform than a one-drug company. Large pharma has recently paid $1.4–$4.1 billion for radiopharmaceutical companies such as Point, Fusion and RayzeBio. Recent radiopharma transactions $MRK $IOVA
View on StockTwits ↗
$MRNA I was wrong. Fundamentals don't matter. 50/50 split with $MRK which is a profitable company, yet mrna gets the sp love. Congrats bulls!
View on StockTwits ↗$MRK Merck’s published late-stage pipeline currently contains no proprietary radiopharmaceutical therapy. Merck pipeline. What is interesting is that Merck has recently advertised multiple oncology positions explicitly seeking radioligand-therapy commercialization and treatment-site experience. That suggests it may be preparing to enter the field. $CATX
View on StockTwits ↗
@Jiha No It wasn't prove it! I tracked the trial protocols from the start (1/3) How CYDY adds Keytruda to the CLOVER Trial Protocol: 1.CTCSA with Merck ($MRK): Negotiate Clinical Trial Collaboration & Supply Agreement to secure Keytruda supply and review scientific rationale. 2.Draft Protocol Amendment: Author extension phase dosing, revised endpoints, and safety parameters. 3.Submit IND Amendment: File updated protocol under CytoDyn's existing IND to the FDA. 4.IRB Approval: Obtain Institutional Review Board and consent form approvals across sites. FDA Review & Clearance: Per 21 CFR 312.30, adding an unapproved combo alters trial design and triggers a mandatory 30-day FDA review. If the FDA does not issue a Clinical Hold within 30 days (or sends a "Study May Proceed" letter), the protocol amendment legally clears to start.
View on StockTwits ↗
🔍𝗙𝗥𝗘𝗦𝗛 𝗖𝗢𝗡𝗚𝗥𝗘𝗦𝗦 𝗕𝗨𝗬𝗦 🔎 Congress Member Maria Salazar just made a new filing. 𝗡𝗲𝘁 𝗪𝗼𝗿𝘁𝗵: ~$3.3M 𝗦𝘁𝗼𝗰𝗸 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼: up 97.50% (𝘪𝘯 𝘭𝘢𝘴𝘵 3 𝘺𝘦𝘢𝘳𝘴) 𝘓𝘢𝘵𝘦𝘴𝘵 𝘛𝘳𝘢𝘥𝘦𝘴: 🔹 $MRK - 𝗡𝗲𝘄 𝗣𝗼𝘀𝗶𝘁𝗶𝗼𝗻 @ $152.2 🔹 $SPCX - 𝗡𝗲𝘄 𝗣𝗼𝘀𝗶𝘁𝗶𝗼𝗻 @ $146.15 🔹 $CB - 𝗦𝗼𝗹𝗱 𝘀𝗼𝗺𝗲 @ $340.92 🔹 $QCOM - 𝗦𝗼𝗹𝗱 𝘀𝗼𝗺𝗲 @ $161.91 Source: hedgefollow.com/congress-stock-tracker
View on StockTwits ↗
$IBRX $MRNA $MRK $PFE $JNJ .....'Turbo-cancers' PSS KNOWS. https://x.com/docBenk12/status/2099104918783098994?s=20
View on StockTwits ↗
$IBRX $NRXP $PFE $MRNA $MRK RFK Jr. knows. JayB knows. DJT knows. https://x.com/RobertKennedyJr/status/2099203137974222886?s=20
View on StockTwits ↗$IBRX $NRXP $PFE $MRNA $MRK .....Beware Big Pharma, Beware Bureaucrats mRNA BAD. SAVE THE CHILDREN 🙏 PSS knows. https://x.com/i/trending/2099295875323277431?s=20
View on StockTwits ↗
$SMMT Gonna keep moving. They've got the real deal, and keep proving it. At Sub-20s $SMMT appears to be very underpriced. Key data that shows improvement over $MRK's Keytruda deserves plenty of attention.
View on StockTwits ↗
@US_Bull , off topic of $Auph.....do you follow $HALO? If so, have you looked into their litigation with $MRK?
View on StockTwits ↗
$ALT $MRK Efinopegdutide Ph2b MASH trial completed Dec 29, 2025 — ~8.5 months ago. Still no public histology data. No publicly visible move into Ph3. If the data are truly stellar, why are we still waiting for the readout 8.5 months after study completion? Time is money, especially in MASH. With truly compelling Ph2b results, you’d expect preparations for Ph3 to be moving fast — not 8+ months of silence. 👀
View on StockTwits ↗
$SLS $JNJ $MRK $ABBV September is recognized worldwide as Blood Cancer Awareness Month and Leukemia and Lymphoma Awareness Month, which includes bringing attention to AML. This month, as we reve in the stock price volatility and FOMO frenzy in an anticipation of REGAL '80th event', may we also take a few moments to remember the 80th 'event' is the end of someone's human life? Assuming REGAL success -- I hope the IDMC / FDA / Company would honor the life of this 'event' and all 79 events before, by expediting REGAL FA and the Accelerated Approval process. I'm sure all 80 events would want it that way.
View on StockTwits ↗
@omega42 @MrBean1234 $SPRY’s neffy is already an FDA-approved, commercial epinephrine product. $AQST’s Anaphylm is not. SPRY also has significant pipeline optionality: its intranasal epinephrine platform is in a Phase 2b study for acute flares of chronic spontaneous urticaria (CSU), with interim data expected in Q1 2027. There is currently no FDA-approved on-demand treatment for acute CSU flares. SPRY also brought in a new CEO and CCO with extensive commercial experience, including years working together at Dynavax $SNY and major pharma company including $MRK. Most importantly, management continues to reiterate a path to cash-flow breakeven by the end of 2027 while aggressively cutting expenses and growing neffy adoption.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.